GlassScriptPhysician profile
Michael Dioquino
NPI 1114597986
$8,374.09
in general payments reported to CMS, 2019-2025
22 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $1,110 · 2023: $1,599 · 2024: $2,286 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,631 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,631.31 |
| Education | $364.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,673.16 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,591.07 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,270.28 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $733.98 | 2021-2025 | Caplyta |
| Gilead Sciences, INC. | $590.03 | 2023-2025 | Yeztugo, Biktarvy |
| E.R. Squibb & Sons, L.L.C. | $574.04 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $332.26 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $297.58 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $230.23 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $218.14 | 2022-2025 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $213.94 | 2024-2025 | Fanapt |
| Merck Sharp & Dohme LLC | $129.86 | 2022-2025 | Pifeltro, Gardasil 9, Capvaxive |
| Emd Serono, INC. | $121.81 | 2025 | |
| Viiv Healthcare Company | $114.28 | 2023-2025 | Dovato, Rukobia |
| Axsome Therapeutics, INC. | $90.39 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $78.20 | 2021-2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.08 | 2024 | |
| Exact Sciences Corporation | $22.62 | 2023 | Cologuard Collection Kit |
| Luye Pharma (USA) LTD. | $19.57 | 2025 | Erzofri Extended-Release |
| Theratechnologies INC. | $17.66 | 2021 | |
| Dynavax Technologies Corporation | $16.07 | 2021 | |
| Validus Pharmaceuticals LLC | $15.84 | 2025 | Raldesy, Equetro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dioquino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.